

Form PTO-1449 (modified)		Atty. Docket No. GOUD:038US	Serial No. 10/671,340
<p>O I P List of Patents and Publications for Applicant's MAY 21 2004 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)</p>		<p>Applicant Denis Gravel <i>et al.</i></p>	
		Filing Date: September 25, 2003	Group: 1614
<p>U.S. Patent Documents <i>See Page 1</i></p>		<p>Foreign Patent Documents <i>See Page 1</i></p>	<p>Other Art <i>See Page 1</i></p>

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>DL</i>	A1	5,512,549	4/30/96	Chen <i>et al.</i>	514	12	10/18/94
<i>DL</i>	A2	5,545,618	8/13/96	Buckley <i>et al.</i>	514	12	12/10/93

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>DL</i>	B1	EP 0 733 644	9/25/96	Europe	—	—	English
<i>DL</i>	B2	WO 91/11457	8/08/91	PCT	—	—	English
<i>DL</i>	B3	WO 99/43707	9/02/99	PCT	—	—	English

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>DL</i>	C1	Adelhorst <i>et al.</i> , "Structure-activity studies of glucagon-like peptide-1," <i>J. Biol. Chem.</i> , 269(9):6275-6278, 1994.
<i>DL</i>	C2	Burcelin <i>et al.</i> , "Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1," <i>Metabolism</i> , 48(2):252-258, 1999.
<i>DL</i>	C3	D'alessio <i>et al.</i> , "Glucagon-like peptide 1 decreases hepatic glucose production independent of insulin and glucagon," <i>Diabetes</i> , 46(suppl 1):29A, 1997.
<i>DL</i>	C4	Deacon <i>et al.</i> , "Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity," <i>Diabetologia</i> , 41:271-278, 1998.
<i>DL</i>	C5	Doyle and Egan, "Glucagon-like peptide-1," <i>Recent Prog. Horm. Res.</i> , 56:377-399, 2001.
<i>DL</i>	C6	Doyle <i>et al.</i> , "Insertion of an N-Terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent," <i>Endocrinology</i> , 142(10):4462-4468, 2001.
<i>DL</i>	C7	Drucker, "Minireview: the glucagon-like peptides," <i>Endocrinology</i> , 142(2):521-527, 2001.

25404463.1

EXAMINER: *Jeffrey E. Russell*DATE CONSIDERED: *January 10, 2005*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. GOUD:038US	Serial No. 10/671,340
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Denis Gravel <i>et al.</i>	
		Filing Date: September 25, 2003	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>gjl</i>	C8	Dugas and Penney, In: <i>Bioorganic Chemistry</i> , Springer-Verlag, NY, 54-92, 1981.
<i>gjl</i>	C9	Gorrell <i>et al.</i> , "CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes," <i>Scand. J. Immunol.</i> , 54:249-264, 2001.
<i>gjl</i>	C10	Gutniak <i>et al.</i> , "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus," <i>The New England Journal of Medicine</i> , 326:1316-1322, 1992.
<i>gjl</i>	C11	Gutniak, "Treatment of diabetes GLP-1: a new kid in town," <i>International Diabetes Monitor</i> , 9(2):1-12, 1997.
<i>gjl</i>	C12	Holst, "Glucagonlike peptide 1: a newly discovered gastrointestinal hormone," <i>Gastroenterology</i> , 107:1848-1855, 1994.
<i>gjl</i>	C13	Holst, "Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signaling nutritional abundance, with an unusual therapeutic potential," <i>Trends Endocrinol. Metab.</i> , 10(6):229-235, 1999.
<i>gjl</i>	C14	Holz <i>et al.</i> , "Activation of a cAMP-regulated Ca <sup>2+</sup> signaling pathway in pancreatic β-cells by the insulinotropic hormone glucagon-like peptide-1," <i>J. Biol. Chem.</i> , 270(30):17749-17757, 1995.
<i>gjl</i>	C15	Kieffer and Habener, "The glucagon-like peptides," <i>Endocrine Reviews</i> , 20(6):876-913, 1999.
<i>gjl</i>	C16	Kreymann <i>et al.</i> , "Glucagon-like peptide-1 7-36: a physiological incretin in man," <i>Lancet</i> , 2(8571):1300-1304, 1987.
<i>gjl</i>	C17	Merrifield, "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide," <i>Chem. Soc.</i> , 85:2149-2154, 1962.
<i>gjl</i>	C18	Nauck <i>et al.</i> , "Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes," <i>Diabetologia</i> , 29:46-52, 1986.
<i>gjl</i>	C19	Nauck <i>et al.</i> , "Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1(7-36 amide) in type 2 (non-insulin-dependent) diabetic patients," <i>Diabetologia</i> , 36:741-744, 1993.
<i>gjl</i>	C20	Nauck, "Glucagonlike peptide 1," <i>Curr. Opin. Endocrinol. Diabet.</i> , 4:291-299, 1997.
<i>gjl</i>	C21	Peptide synthesis protocols, Methods in molecular biology, Vol. 35, Pennington and Dunn (eds.), Humana Press, 1994.

25404463.1

EXAMINER: *Jeffrey E. Russell*DATE CONSIDERED: *January 10, 2005*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. GOUD:038US	Serial No. 10/671,340
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Denis Gravel <i>et al.</i>	
		Filing Date: September 25, 2003	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>DR</i>	C22	Perfetti and Merkel, "Glucagon-like peptide-1: a major regulator of pancreatic $\beta$ -cell function," <i>European Journal of Endocrinology</i> , 143:717-725, 2000.
<i>DR</i>	C23	Remington's <i>Pharmaceutical Sciences</i> , 15 <sup>th</sup> ed., 33:624-652, Mack Publishing Company, Easton, PA, 1980.
<i>DR</i>	C24	Scrocchi <i>et al.</i> , "Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene," <i>Nature Medicine</i> , 2(11):1254-1258, 1996.
<i>DR</i>	C25	Siegel <i>et al.</i> , "Biological activity of GLP-1-analogues with N-terminal modifications," <i>Regulatory Peptides</i> , 79:93-102, 1999.
<i>DR</i>	C26	Stewart and Young, In: <i>Solid Phase Peptide Synthesis</i> , 24-66, Freeman, San Francisco, 1969.
<i>DR</i>	C27	Suzuki <i>et al.</i> , "Effects of GLP-1 and its fragment peptides on pancreatic hormone release," <i>Diabetes Res.</i> , 5(Suppl 1):S30, 1988.
<i>DR</i>	C28	Toft-Nielsen <i>et al.</i> , "Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients," <i>Diabetes Care</i> , 22:1137-1143, 1999.
<i>DR</i>	C29	Tolessa <i>et al.</i> , "Inhibitory effect of glucagon-like peptide-1 on small bowel motility," <i>J. Clin. Invest.</i> , 102(4):764-774, 1998.
<i>DR</i>	C30	Wang <i>et al.</i> , "Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats," <i>J. Clin. Invest.</i> , 99(12):2883-2889, 1997.
<i>DR</i>	C31	Xiao <i>et al.</i> , "Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo," <i>Biochemistry</i> , 40:2860-2869, 2001.
<i>DR</i>	C32	Xu <i>et al.</i> , "Exendin-4 stimulates both $\beta$ -cell replication and neogenesis, resulting in increased $\beta$ -cell mass and improved glucose tolerance in diabetic rats," <i>Diabetes</i> , 48:2270-2276, 1999.

25404463.1

EXAMINER: <i>Jeffrey E. Russell</i>	DATE CONSIDERED: <i>January 10, 2005</i>
-------------------------------------	--

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.  
GOUD:038USSerial No.  
10/671,340

List of Patents and Publications for Applicant

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
Denis Gravel *et al.*Filing Date:  
September 25, 2003Group:  
1614U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 1*

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>SR</i>	B4	WO 00/55119	9/21/00	PCT			English
<i>JR</i>	B5	WO 02/10195	2/07/02	PCT			English
<i>JR</i>	B6	WO 98/08871	3/05/98	PCT			English

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25433356.1

EXAMINER: *Jeffrey E. Russel*DATE CONSIDERED: *January 10, 2005*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.